Immunocore Holdings plc
IMCR
$31.16
-$0.05-0.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.75% | 24.37% | 24.32% | 26.54% | 31.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.75% | 24.37% | 24.32% | 26.54% | 31.02% |
| Cost of Revenue | -65.56% | -487.69% | -101.13% | -108.59% | -121.70% |
| Gross Profit | 29.24% | 48.08% | 219.01% | 219.79% | 242.29% |
| SG&A Expenses | 3.62% | 7.81% | -6.21% | 7.96% | 14.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2,112.37% | -2,112.37% | 12,914.29% | 12,914.29% | 12,914.29% |
| Total Operating Expenses | 7.55% | 16.98% | 17.14% | 29.72% | 35.28% |
| Operating Income | 59.17% | 13.44% | 6.15% | -43.28% | -53.60% |
| Income Before Tax | 65.40% | 13.06% | -5.94% | -29.63% | -67.98% |
| Income Tax Expenses | 79.31% | 66.98% | -137.17% | -125.31% | -139.93% |
| Earnings from Continuing Operations | 64.12% | 7.60% | 31.62% | 12.02% | -13.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.12% | 7.60% | 31.62% | 12.02% | -13.62% |
| EBIT | 59.17% | 13.44% | 6.15% | -43.28% | -53.60% |
| EBITDA | 62.62% | 14.61% | 6.07% | -49.94% | -66.27% |
| EPS Basic | 64.53% | 9.74% | 33.70% | 14.51% | -9.36% |
| Normalized Basic EPS | 63.37% | 21.13% | -6.44% | -31.16% | -66.99% |
| EPS Diluted | 64.15% | 9.37% | 33.33% | 15.42% | -8.00% |
| Normalized Diluted EPS | 62.89% | 20.71% | -6.92% | -29.78% | -64.96% |
| Average Basic Shares Outstanding | 1.49% | 2.26% | 2.79% | 3.47% | 5.39% |
| Average Diluted Shares Outstanding | 1.26% | 1.08% | 1.59% | 3.69% | 5.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |